Sunshine Biopharma (SBFM) Total Liabilities (2010 - 2026)

Sunshine Biopharma has reported Total Liabilities for 17 years, with the latest figure at $6.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 1.09% year-over-year to $6.4 million; the trailing twelve-month figure through Mar 2026 stood at $6.4 million (down 1.09% YoY), and the FY2025 full-year result was $7.0 million, changed 0.27% from the prior year.
• Total Liabilities for Q1 2026 stood at $6.4 million, down from $7.0 million in the prior quarter.
• The five-year high for Total Liabilities was $7.6 million in Q4 2022, with the low at $95234.0 in Q1 2022.
• Historically, Total Liabilities has averaged $5.4 million across 5 years, with a median of $6.3 million in 2025.
• Annual changes were most pronounced in 2022 — Total Liabilities slumped 96.76% — and 2023, when it surged 7840.3%.
• Sunshine Biopharma's Total Liabilities stood at $7.6 million in 2022, then decreased by 19.39% to $6.1 million in 2023, then gained by 14.99% to $7.1 million in 2024, then retreated by 0.27% to $7.0 million in 2025, then retreated by 8.9% to $6.4 million in 2026.
• The last three Total Liabilities figures came in at $6.4 million (Q1 2026), $7.0 million (Q4 2025), and $7.3 million (Q3 2025), per Business Quant data.